https://www.selleckchem.com/pr....oducts/sulfosuccinim
Combination therapy with docetaxel and androgen deprivation therapy (ADT) prolongs overall survival (OS) in men with metastatic hormone-sensitive prostate cancer. We assessed the benefits and adverse effects of docetaxel and ADT in relation to advancing age. We performed a post hoc analysis of the CHAARTED trial comparing docetaxel and ADT vs. ADT alone (n=773). Patients were stratified in age groups 60, 60-70, and 70 years old. Multivariable-adjusted progression-free survival (PFS) and OS were assessed u
Beğen
Yorum Yap
Paylaş
